FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C	20549	
vvasiliigton,	D.C.	20049	

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	e condition ee Instructi																			
Name and Address of Reporting Person*     Ma Songjiang							2. Issuer Name and Ticker or Trading Symbol  GYRE THERAPEUTICS, INC. [ GYRE ]									k all app Direc	tor	ng Per	10% O	wner
(Last) (First) (Middle) C/O GYRE THERAPEUTICS, INC. 12770 HIGH BLUFF DRIVE, SUITE 150						01/0	3. Date of Earliest Transaction (Month/Day/Year) 01/02/2025									Officer (give title below)  President  Other (specify below)				
(Street) SAN DIEGO CA 92130						4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi	,				
(City)		(Sta	te) (2	Zip)																
			Table	I - No	on-Deriva	tive S	Secu	rities	Acc	quired	l, Dis	sposed of	, or B	enef	icially	<b>Own</b>	ed			
Date				2. Transacti Date (Month/Day	Exe //Year) if a		2A. Deemed Execution Date, if any (Month/Day/Year)				4. Securities Disposed Of				5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
										Code	v	Amount	(A) or (D)			Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock 01					01/02/20	1/02/2025				S <sup>(1)</sup>		2,000	D	\$1	2.4 <sup>(2)</sup>	2,9	920,467		I	By Spouse
Common Stock 01/03/2				)25				S <sup>(1)</sup>		1,167	D	\$11	.03(3)	2,9	919,300		I	By Spouse		
Common Stock 01/					01/03/20	024				<b>S</b> <sup>(1)</sup>		833	D	\$11	.85(4)	2,918,467		I		By Spouse
			Tal	ole II	- Derivati (e.g., pu	ve Se its, ca	ecurit alls, v	ies / varra	Acqu ants,	ired, optic	Disp ons,	osed of, o	or Be le sec	nefic curiti	ially ( es)	Owne	d			
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date Security or Exercise (Month/Day/Year) if any				ition Date,	4. Transa Code ( 8)			6. Date Exer Expiration D (Month/Day/		ate	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Dei Sed (Ins	ivative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
							v	(A)	(D)	Date Exerci	isable	Expiration Date	Amou or Numb of Title Share		er					

## **Explanation of Responses:**

- 1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- 2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from \$11.99 to \$12.80. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- 3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from \$10.73 to \$11.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- 4. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from \$11.73 to \$12.27. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

/s/ Songjiang Ma

01/06/2025

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.